Rubraca® (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Recept

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/4/2026

1. KRG
2. PRY:IM
3. PRYMY
4. SPY
5. SKA-B
6. PBA
7. ALAR
8. CCH:LN
9. META
10. CCHGY

Go back to Rubraca® (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Recept

Clovis Oncology (CLVS) PT Raised to $33 at H.C. Wainwright

May 18, 2020 7:47 AM EDT

H.C. Wainwright analyst Edward Wright raised the price target on Clovis Oncology (NASDAQ: CLVS) to $33.00 (from $29.00) while maintaining a Buy rating.

The analyst commented, "On Friday, Clovis announced that the FDA granted accelerated approval for Rubraca in patients with BRCA1/2-mutant, metastatic castration-resistant prostate cancer (mCRPC) patients who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The label was as we had expected with no surprises. Rubraca is Clovis oral,... More